Steve Swanson to Speak at Immunotoxicity Conference Jan 31 - Feb 1, 2013 in San Diego, CA

MONROVIA, CA, November 10, 2012 (Press-News.org) Steve Swanson, Executive Director and Head of Clinical Immunology at Amgen, will give a featured presentation entitled "Immunogenicity Assessment of Therapeutic Proteins: Where We Are and Where We are Headed", at the Inaugural Immunogenicity and Immunotoxicity conference to be held on Jan 31 - Feb 1, 2013 in San Diego, CA.

Dr. Swanson joined Amgen in 1999 to build the Clinical Immunology Department whose mission was to focus on anti-therapeutic antibody issues. This department supports functions including development, validation, and performance of all immunoassays and bioassays for the detection of antibodies directed against Amgen's therapeutic proteins. This work includes analysis of preclinical and clinical samples generated to support drug development. In addition, the cellular immunology group within Clinical Immunology investigates cellular interactions through FACS, LSC, confocal microscopy, and other imaging techniques and contributes to biomarker work to support product development. Clinical Immunology is also responsible for the management of Amgen's biological samples.

The Inaugural Immunogenicity and Immunotoxicity conference will bring together a mix of academic and industry experts from leading affiliations (such as MedImmune, Roche, Ambryx, Aegis Therapeutics, Antitope, Epiontis, Amgen, EpiVax, Ablynx, Eleven Biotherapeutics, Bayer HealthCare and more) to cover many current and relevant aspects of Immunogenicity and Immunotoxicity.

In addition to Steve Swanson's featured presentation, Jack Ragheb from the Therapeutic Proteins Office of Biological Products at the FDA will also present. The keynote address will be given by Anne De Groot from EpiVax.

This conference is also part of the 2nd Novel Cancer Therapeutic Summit, which consists of this track and three other tracks:

1) 5th Immunotherapeutics and Immunomonitoring
2) 11th Cytokines and Inflammation
3) 2nd Allergy Drug Discovery

For more information, please visit http://www.gtcbio.com

ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com